Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ: VRTX )

495.42 +7.08 (+1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
58 59 Next >
Is Vertex Pharmaceuticals Stock a Buy Now?
The company is close to another breakthrough. 
Via The Motley Fool
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
What 10 Analyst Ratings Have To Say About Vertex Pharmaceuticals
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
You might not get a better chance to invest in these disruptive companies. 
Via The Motley Fool
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher
These stocks look reasonably priced today considering their long-term prospects. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Most stocks aren't truly revolutionary. These really are. 
Via The Motley Fool
1 No-Brainer Stock to Buy and Hold for 10 Years
This company has been in the news for much of the year. 
Via The Motley Fool
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
Why you can make Vertex Pharmaceuticals a buy on any pullback
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
Via MarketBeat
Exposures COVID-19
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex. 
Via The Motley Fool
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
Via Investor's Business Daily
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates. 
Via Benzinga
Topics Earnings
Exposures Financial
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Reports Third Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
The meeting went almost as well as could be expected. 
Via The Motley Fool
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.